Vaxcyte, Inc.
NASDAQ Global SelectCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- CEO
- Grant E. Pickering
- Full Time Employees
- 414
- Sector
- Healthcare
- Industry
- Biotechnology
- Address
- 825 Industrial Road San Carlos CA United States of America 94070
- IPO Date
- Jun 12, 2020
- CIK
- 0001649094
- Website
- vaxcyte.com
- Similar Companies
- Business
- Vaxcyte, Inc. is a clinical-stage vaccine innovation company specializing in engineering high-fidelity vaccines to protect against bacterial infectious diseases. Its core products include broad-spectrum pneumococcal conjugate vaccines (PCVs), notably VAX-24, a 24-valent vaccine aimed at preventing invasive pneumococcal disease, and VAX-31, a PCV with expanded coverage of over 30 strains designed for infants and adults. The company also develops other vaccine candidates such as VAX-A1, a prophylactic vaccine for Group A Streptococcus infections; VAX-PG, a therapeutic vaccine for periodontal disease; and VAX-GI, targeting dysentery and shigellosis. These products leverage site-specific, carrier-sparing conjugation technology to provide protection against both currently circulating and historically prevalent strains. Vaxcyte operates primarily in the United States and has pipeline products targeting public health segments involving bacterial infections, oral health, and infectious disease prevention. Founded in 2015 and headquartered in San Carlos, California, Vaxcyte has recently made significant strategic advances. In 2025, the company established a major fill-finish manufacturing partnership with Thermo Fisher Scientific valued at up to $1 billion to expand domestic commercial manufacturing capacity for its pneumococcal vaccines in Greenville, North Carolina, enhancing its U.S. supply chain and commercial readiness. This move supports U.S. biomanufacturing capabilities and anticipates upcoming product commercialization. Additionally, Vaxcyte is advancing clinical development milestones, including initiation of a pivotal Phase 3 adult study for VAX-31 in late 2025 and reporting of final Phase 2 positive dose-finding results for VAX-24 in infants. The FDA has granted Breakthrough Therapy designation to VAX-31 for pneumonia prevention, underscoring its clinical potential. The company maintains a strong cash position to fund operations through mid-2028 and recently appointed a Chief Commercial Officer to support commercialization efforts. Vaxcyte targets markets involving pneumococcal disease prevention, Group A strep infections, periodontal disease treatment, and gastrointestinal bacterial diseases across the United States and potentially global regions as its vaccines advance through regulatory approvals. Its product pipeline and manufacturing expansions position it competitively in the biotech vaccine sector, focused on broad-spectrum and high-fidelity vaccine innovation designed to address significant unmet medical needs in bacterial infectious diseases. This description synthesizes Vaxcyte’s business scope, product portfolio, recent strategic developments including manufacturing expansion, and clinical progress as of late 2025.
Vaxcyte Doses First Participant in Phase 1 Study Evaluating VAX-A1 for the Prevention of Disease Caused by Group A Streptococcus in Healthy Adults
Vaxcyte, Inc. (PCVX) Presents at Bank of America Global Healthcare Conference 2026 Transcript
Vaxcyte Reports First Quarter 2026 Financial Results and Provides Business Update
Vaxcyte's Manufacturing-Backed Vaccine Platform Is Redefining The PCV Market
Vaxcyte to Present at the 25th Annual Needham Virtual Healthcare Conference
Vaxcyte Completes Enrollment of OPUS-1 and OPUS-2 Phase 3 Trials Evaluating VAX-31 for the Prevention of Invasive Pneumococcal Disease and Pneumonia in Adults
Positive VAX-31 Phase 1/2 Adult Data Published in The Lancet Infectious Diseases Highlight Best-in-Class Potential of Vaxcyte's 31-Valent Pneumococcal Conjugate Vaccine (PCV) Candidate
Bridgefront Capital LLC Increases Stock Holdings in Vaxcyte, Inc. $PCVX
Citigroup Inc. Sells 116,206 Shares of Vaxcyte, Inc. $PCVX
Vaxcyte, Inc. (PCVX) Q4 2025 Earnings Call Transcript
Vaxcyte Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update
Vaxcyte, Inc. $PCVX Shares Sold by China Universal Asset Management Co. Ltd.
Vaxcyte Spotlights VAX-31 Phase 3 Launch, Eyes Adult BLA by End of Next Year at Biotech Summit
Vaxcyte Doses First Participants in OPUS-3 Phase 3 Trial Evaluating VAX-31 in Adults Previously Vaccinated with Lower-Valency Pneumococcal Vaccines
Vaxcyte to Report Fourth Quarter and Full Year 2025 Financial Results and Provide Business Update on February 24, 2026
Vaxcyte, Inc. $PCVX Shares Bought by Federated Hermes Inc.
Vaxcyte to Present at the Guggenheim Emerging Outlook: Biotech Summit
Vaxcyte Announces Closing of $632.5 Million Public Offering Including Full Exercise of Underwriters' Option to Purchase Additional Shares
Vaxcyte Announces Pricing of $550 Million Public Offering
Harbor Small Cap Growth Fund Q4 2025 Portfolio Performance